HCM
HUTCHMED (China) Limited
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · HK
$14.09
−0.14%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 549.1M | 550.0M | 630.2M | 838.0M | 426.4M |
| Cost of Revenue | 548.0M | 337.2M | 347.6M | 384.4M | 311.1M |
| Gross Profit | 1.1M | 212.7M | 282.6M | 453.6M | 115.3M |
| Operating Expenses | |||||
| R&D Expense | 161.5M | 164.1M | 213.4M | 303.1M | 386.9M |
| SG&A Expense | 107.9M | 103.3M | 112.9M | 133.2M | 136.1M |
| General & Admin Expense | 70.8M | 67.0M | 64.3M | 79.8M | 92.2M |
| Selling & Marketing Expense | 37.1M | 36.3M | 48.6M | 53.4M | 43.9M |
| Other Expenses | (233.5M) | — | — | — | 311.1M |
| Total Operating Expenses | 35.9M | 267.4M | 326.3M | 436.2M | 834.1M |
| Cost and Expenses | 583.9M | 604.7M | 673.9M | 819.6M | 1.1B |
| Operating Income (EBIT) | (34.8M) | (54.7M) | (43.7M) | 18.4M | (718.8M) |
| Non-Operating | |||||
| Interest Income | — | 50.0M | 40.1M | 36.1M | 9.6M |
| Interest Expense | — | 2.9M | 2.9M | 759.0K | 652.0K |
| Net Interest Income | — | 47.1M | 37.2M | 35.4M | 8.9M |
| Other Non-Op Income/Expense | 54.9M | 577.4M | 89.1M | 87.2M | 358.1M |
| Non-Operating Income (excl Interest) | — | — | — | — | (358.8M) |
| EBT (Pre-Tax Income) | 20.1M | 522.7M | 45.4M | 105.6M | (360.7M) |
| Income Tax Expense | 1.7M | 63.8M | 7.2M | 4.5M | (283.0K) |
| Bottom Line | |||||
| Net Income | 17.9M | 458.1M | 37.7M | 100.8M | (360.8M) |
| Earnings from Cont. Ops | 18.4M | 458.9M | 38.2M | 101.1M | (360.4M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 17.9M | 458.1M | 37.7M | 100.8M | (360.8M) |
| Per Share | |||||
| Basic EPS | $0.10 | $2.65 | $0.22 | $0.60 | ($2.15) |
| Diluted EPS | $0.10 | $2.60 | $0.22 | $0.60 | ($2.15) |
| Revenue Per Share | $3.17 | $3.20 | $3.68 | $4.93 | $2.52 |
| Shares | |||||
| Basic Shares Outstanding | 173.2M | 171.7M | 171.1M | 169.9M | 169.4M |
| Diluted Shares Outstanding | 174.6M | 174.6M | 174.6M | 173.8M | 169.4M |
| Profitability Metrics | |||||
| EBITDA | (20.5M) | (41.4M) | (31.4M) | 26.6M | (360.0M) |
| D&A | 14.3M | 13.3M | 12.3M | 8.2M | — |
| EBIT | (34.8M) | (54.7M) | (43.7M) | 18.4M | (360.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026